Anxiety DisordersDepressive DisordersMicrodosing

Powerful substances in tiny amounts An interview study of psychedelic microdosing

This qualitative interview study of 21 male psychedelic microdosers found many deliberately used sub‑perceptual doses in phases to enhance everyday functioning, reporting improvements in mood, cognition and creativity that helped counter anxiety and depression, although some experienced challenges or stopped. The findings are not generalisable but may inform future research questions and hypotheses.

Authors

  • Johnstad, P. G.

Published

Nordic Studies on Alcohol and Drugs
individual Study

Abstract

Aims: This article presents a qualitative interview study of people who microdose with psychedelic drugs, which means that the user takes about one tenth of an ordinary recreational dose. Design: Respondents ( n = 21) were recruited at several Internet fora for individual interviews via private messaging. Every participant was male, and the median respondent was in his 30s with a stable job and relationship and extensive entheogen experience. Results: Respondents tended to experiment with microdosing in phases, reporting mostly positive consequences from this form of drug use. Reported effects included improved mood, cognition, and creativity, which often served to counteract symptoms especially from conditions of anxiety and depression. There were also reports of various challenges with psychedelic microdosing, and some did not find the practice worth continuing. Conclusion: The study obtained evidence of a group of users taking small doses of psychedelics not for the purpose of intoxication but to enhance everyday functioning. While the study’s findings are not generalisable, they may inform subsequent investigations with research questions and hypotheses.

Unlocked with Blossom Pro

Research Summary of 'Powerful substances in tiny amounts An interview study of psychedelic microdosing'

Introduction

Microdosing with psychedelic drugs refers to taking doses small enough to avoid intoxication or significant alteration of consciousness. Grahl situates the phenomenon within recent popularisation on the Internet and media reports that claim improvements in concentration, creativity and mood from sub‑perceptual doses, while noting that, at the time of the study, no peer‑reviewed research specifically addressed psychedelic microdosing. He contrasts microdosing with the larger, clinical psychedelic doses that have shown therapeutic promise but can induce intense experiences and, in some cases, acute adverse reactions. The study set out to explore how users approach psychedelic microdosing and to identify recurring patterns or themes in their reports. Grahl framed the investigation as exploratory and hypothesis‑generating: by interviewing self‑selected microdose users about regimens, perceived benefits, and problems, the research aimed to supply questions and directions for subsequent clinical or quantitative studies. He also related microdosing to broader debates about human enhancement versus therapy, to clarify potential motivations behind use.

Methods

The study used purposive sampling to recruit current or former microdose users from seven Internet discussion fora focused on psychedelic experiences. Recruitment combined public invitation threads and targeted private messages to forum members who had contributed to microdosing discussions; 24 forum members were contacted and 21 consented to participate. Ethical procedures conformed to Norwegian Social Science Data Services guidelines, and the author emphasised participant anonymity to reduce risk given the illegal status of psychedelics. Interviews were asynchronous, Internet‑mediated and semi‑structured, typically conducted by email. Typical guiding questions covered which psychedelics had been microdosed, experience length, dosing schedules, effects, negative effects, and next‑day consequences. Recruitment continued until the author judged that new responses repeatedly conformed to earlier patterns (i.e. thematic saturation). Transcription was unnecessary because the communication was written. Data analysis combined thematic analysis with a procedure described as meaning condensation. Participant statements were shortened, grouped by topic (for example usage patterns, therapeutic effects, negative side effects) and used to construct themes in an open‑ended, data‑driven comparative approach. There was no overarching theoretical interpretive framework; statements were accepted at face value but follow‑up questions were used to resolve ambiguities. The author invited participants to verify use of their quotations. The extracted text reports demographic and experience details unevenly: every respondent was male, 17 reported age with a median in the early 30s, occupational and educational details were provided by some, and psychedelic experience ranged from one to 25 years with a median around 10 years. Thirteen participants had extensive microdosing experience and eight had experimented more sporadically.

Results

Sample and recruitment features. Twenty‑one male participants completed the interviews; demographic data were incomplete by design to protect anonymity. Of 17 who provided age information, the median was in the early 30s. Occupational status varied (students, full‑time employees across diverse jobs, one self‑employed, two unemployed/disabled) and five held master’s degrees or PhDs. Participants’ lifetime experience with psychedelics ranged broadly, and most had substantial prior entheogen experience. Regimens and substances. The dominant substances for microdosing were psilocybin‑containing mushrooms and LSD; other reported agents included Salvia divinorum, Amanita muscaria, Peganum harmala (Syrian rue), San Pedro cactus, DMT, DOM, and cannabis. Typical microdoses were about one tenth of a common full dose: for LSD roughly 10–25 mcg and for Psilocybe cubensis mushrooms about 0.1–0.3 g. Many users adopted cyclic regimens lasting weeks to months, dosing one to three times per week; some reported daily dosing. Reports on tolerance varied—several users did not perceive tolerance build‑up with intermittent dosing, while daily users sometimes reported tolerance or headaches. Therapeutic effects. The majority of respondents reported at least some positive effects from microdosing. Most prominently, participants described improvements in mood and reductions in symptoms of anxiety and depression, with several reporting relief they judged superior or preferable to prescribed pharmaceuticals. A smaller number described benefits for conditions such as obsessive‑compulsive disorder, post‑traumatic stress disorder, narcolepsy, migraines and chronic pain, and some credited certain psychedelics with helping smoking cessation. Reports were often drug‑specific (for example, one respondent said certain mushroom species worked better for pain than others). Enhancement effects and social/creative functioning. Beyond clinical complaints, many users described perceived enhancement of energy, cognitive clarity, creativity, productivity and social openness. Some used microdosing deliberately to boost academic or workplace performance. Users generally distinguished subjective differences between LSD and psilocybin microdoses: LSD was commonly described as more stimulating, which some found useful and others found uncomfortable; psilocybin was often characterised as subtler and more personal. Aftereffects varied widely: some reported a normal day after dosing, others an ‘‘afterglow’’ resembling the positive residuals of a full dose, and at least one reported sustained anxiety relief for up to a week after a cycle. Challenges and adverse reports. Several participants highlighted practical and safety concerns. The most common problem was accidental overdosing into a mini‑dose that produced noticeable intoxication—this risk arises from imprecise blotter cutting for LSD and variable psilocybin content in mushrooms. Insomnia and overstimulation, particularly with LSD microdoses taken late in the day, were reported by multiple respondents. A few users described longer‑term loss of benefit or even worsening mental‑health symptoms after extended use, and one participant recounted a ‘‘bad trip’’ when combining a microdose with cannabis. Participants also expressed unease about the unknown effects of long‑term microdosing.

Discussion

Grahl interprets the interviews as an account of a subgroup of relatively resourceful, Internet‑engaged male psychedelic users who microdose mainly to enhance mood, cognition and everyday functioning, and sometimes to self‑manage clinical symptoms. He emphasises that the sample is not representative and that findings do not support generalisable claims, but suggests the reported patterns can inform hypotheses for clinical research. The discussion highlights parallels between psychedelic microdosing and other forms of cognitive enhancement drug use: both can be motivated by performance optimisation in work or study, and both blur the line between therapy and enhancement. Grahl notes that some respondents used microdosing explicitly to address diagnosable conditions, while others sought generalised enhancement; the distinction was often ambiguous. He recommends that initial clinical research on microdosing prioritise investigation of putative anxiolytic and antidepressant effects. Safety and practical implications are addressed pragmatically. The author points out dosing‑accuracy and potency‑variability problems as principal safety concerns and suggests that clinical applications could mitigate these by providing standardised microdoses, while acknowledging that such control cannot prevent intentional multiple‑dosing by users. He also stresses that negative experiences—though a minority—do occur and that interactions with other drugs (notably cannabis) may potentiate adverse reactions. Methodological caveats and recruitment reflections. Grahl acknowledges multiple limitations: Internet recruitment likely selected for more educated, reflective and pro‑psychedelic participants; all respondents were male; anonymity constraints limited collection of demographic detail; and the study design cannot distinguish pharmacological effects from expectation (placebo/nocebo). He nevertheless argues that Internet fora are a valuable recruitment arena for accessing this hidden population and that the specific, variable reports increase confidence that respondents were describing distinct drug‑specific effects. The study is offered primarily as an exploratory contribution to shape future, controlled investigations into microdosing.

View full paper sections

CONCLUSION

The purpose of this study was to explore how "ordinary" users of psychedelics approach psychedelic microdosing. The selection of users included in this study was not, however, representative of the population of psychedelics users, and the findings of the study therefore have no claim to general validity. Despite this shortcoming, the findings may serve to acquaint researchers with the, as of yet, understudied phenomenon of psychedelic microdosing. The microdosing practices reported in this study generally conformed in regimen and dose to the recommendations published by, although some users experimented with daily microdoses. LSD and psilocybincontaining mushrooms were most commonly used, but some respondents also microdosed a wide range of lesser-known psychedelics and other psychoactive drugs. Respondents for the most part reported what they regarded as positive effects from microdosing, with few side effects. Microdoses most commonly served as mood and cognitive enhancers, allowing people to function at what they felt was a higher level than usual. There are clear parallels between psychedelic microdosing and the use of cognitive enhancement drugs among healthy individuals for performance improvements described byand, as both forms of drug use can be motivated by a wish for enhanced performance in the workplace or in academic study. However, there was also a therapeutic motivation for psychedelic microdosing among some of the respondents in this study who suffered from conditions such as anxiety or depression. These findings are congruent with reported effects from full doses of psychedelic drugs on conditions of depression and anxiety. Reports about the efficacy of microdosing practices for conditions such as substance dependence, OCD, and PTSD also have parallels in research on therapeutic effects from psychedelics in full doses. It should be noted, however, that in the present study these observations were limited to one or a few individuals. Clinical research on microdosing should probably first look into putative anxiolytic and antidepressive effects, but need not end there. The lack of a clear distinction between therapy and enhancement that has been pointed to by anthropologists and sociologists who study enhancement technologiesis echoed in this study. Some respondents pointed to specific deficiencies that their use of psychedelic microdoses was intended to address, but there was an overlap between the use motivated by such therapeutic effects and the use motivated by an effect of enhancement. In either case, the desired effect from microdosing was to be lifted out of a state of relative limitation into a state of higher functioning. The difference was that in therapeutic use, the state of limitation corresponded with a specific medical diagnosis. One respondent explicitly challenged the notion that his "normal" or pre-microdosing state of being deserved the designation "healthy", even though he had not been diagnosed with any specific ailment. Some respondents experienced no effects from microdosing at all, however, and several others emphasised that, despite their positive experience, microdosing is no miracle cure. There were some indications that psychedelic microdoses might not retain their perceived beneficial effects over longer stretches of time, and that the use should therefore be constrained to phases, which was indeed the most common approach to microdosing among respondents with extensive experience. This reduction of effect over time might limit the medical value of microdosing psychedelics, and would seem to be an important area of investigation for subsequent clinical research of microdosing. The most commonly reported challenges with microdosing were overdosing and insomnia. Overdosing in this case means going beyond microdose territory into a mini-dose that has some intoxicating effect. Such mini-doses are not by themselves overly problematic for experienced psychedelics users, but might have serious negative consequences for users who combine microdosing with work, driving a car, and other activities not compatible with drug intoxication. The overdosing problem applies both to LSD and to psilocybincontaining mushrooms. The former is fully active in doses of a hundred micrograms, and a microdose is often obtained, rather inexactly, by cutting a blotter into separate pieces. Mushrooms for their part may be subject to a natural variation in psilocybin content. Clinical applications of microdosing could solve this problem by supplying standardised microdoses, but would have to trust their clients not to take several doses at the same time. The few negative reports about microdosing in this study were not apparently a result of overdosing, nor is there any other obvious explanation for their occurrence. While these negative experiences constitute a minority, it is important to note that some people may experience distinctly unpleasant effects as a result of microdosing. The reported "bad trip" might appear to be a product more of cannabis use than of the LSD microdose, but damagereduction publications such as tripsafe.org often warn that cannabis might potentiate psychedelic drugs. The question of whether microdosing of psychedelic drugs should be characterised as "abuse", which waslabel for piracetam use among healthy individuals, or as "functional drug use", whichargued is the best way to understand the use of cognitive enhancement drugs, is not easily answered. Psychedelics are designated as drugs of abuse in most of the world, but there is a substantial research literature that indicates that their use may have therapeutic effect. It is possible that microdosing may allow users to procure some of the perceived positive effects of these drugs while avoiding the problems that may follow from taking them in full doses. As a social phenomenon, we can perhaps understand psychedelic microdosing in light ofobservation that the cultural authority of medical experts may be subject to change. Much medical knowledge is now readily available on the Internet, and electronic fora for psychedelic users serve as knowledge repositories that integrate shared user experiences with medical and neuroscientific information. This has resulted in increased knowledge availability (or at least in the perception of increased knowledge availability), which may have caused a corresponding decrease in the cultural authority of medical experts. The growth of microdosing may therefore reflect a social development in which ordinary people use the Internet for medical advice and feel empowered to take personal responsibility for their medication needs, pursuing therapy and enhancement through means that the medical establishment does not recognise and would perhaps frown upon. There are no published studies on microdosing with which the findings of this study may be compared. The reports of therapy and enhancement, which constitute the majority here, conform to the findings of previously published anecdotal reports, while the reports of no effect or negative effect are, as far as I can determine, without counterpart. This may reflect a bias towards beneficial effects in anecdotal reports, whichfound to be a problem for media reports about enhancement drugs, or perhaps it may be that the method used in this study has been more conducive to obtaining balanced information. There is no way to differentiate between drug effects and positive or negative expectation effects (placebo/nocebo) in these data, but the study affords an understanding of how "ordinary" users of psychedelics approach psychedelic microdosing. Several respondents expressed nuanced views about the relative benefits and disadvantages of microdosing that were not in any obvious manner indebted to placebo or nocebo effects. They also reported discovering specific practices that have worked well for them, compared to others that were found to be ineffectual or subject to negative side effects. Confidence in the reports is therefore increased by their high degree of specificity, as curative or symptom-abating effect was often reported only for one of several drugs that respondents used. Another overall finding from this study is the value of tapping the psychedelic Internet community for academic studies. It is unknown whether this segment of Internet-active users is representative of the general psychedelicusing population, but the discussion fora frequented by these users are probably among the best recruitment arenas available to researchers. The respondents in this study were reflective, knowledgeable, and fully capable of expressing their views, and their participation would be an asset to any study of psychedelic drug use. It is possible, however, that a less erudite group of psychedelics users would have a less constructive and self-reflective approach to microdosing, and the study has nothing to say about the attractions of microdosing to women. The findings from this study should therefore be taken to reflect the microdosing experiences of a resourceful group of male psychedelic users, and have value primarily to the extent that they may provide subsequent investigations with research questions and hypotheses.

Study Details

Your Library